NCT03003416 (Louvre 3) is a clinical trial of dexamethasone intravitreal implant in Diabetic Macular Edema, sponsored by Allergan.

Who is sponsoring NCT03003416?

NCT03003416 is sponsored by Allergan.

What drugs are being tested in NCT03003416?

Interventions in NCT03003416: dexamethasone intravitreal implant.

What condition does NCT03003416 study?

NCT03003416 studies Diabetic Macular Edema.

Is NCT03003416 still recruiting?

NCT03003416 is currently completed. Last updated 14 March 2019.

Last reviewed 2019-03-14 · How we verify

NCT03003416: Louvre 3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)

Completed Last updated 14 March 2019

What this trial tests

trial testing dexamethasone intravitreal implant in Diabetic Macular Edema in 115 participants. Completed in 19 December 2018.

Timeline

19 October 2017

Primary endpoint
19 December 2018

19 December 2018

Quick facts

Lead sponsor	Allergan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	115
Start date	19 October 2017
Primary completion	19 December 2018
Estimated completion	19 December 2018
Sites	25 locations across France

Drugs / interventions tested

dexamethasone intravitreal implant — full drug profile →

Conditions studied

Diabetic Macular Edema — all drugs for Diabetic Macular Edema →

Sponsor

Allergan — full company profile →

Who can join

18 and older, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective, Observational, Multicenter, Real-World Study of the Efficacy, Safety, and Pattern of Use of the Dexamethasone Intravitreal Implant in Diabetic Macular Edema in France: Short-Term Outcomes of LOUVRE 3.
Kodjikian L, Delcourt C, Creuzot-Garcher C, Massin P, et al · · 2023 · cited 6× · PMID 36967448 · DOI 10.1007/s40123-023-00662-8

Verify or expand the search:

Other trials of dexamethasone intravitreal implant

Trials testing the same drug.

NCT02951975 — Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye · terminated
NCT02731911 — Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study · completed
NCT01427751 — Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion · Phase 4 · completed

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting

Other Allergan trials

Trials by the same sponsor.

NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03003416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 14 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03003416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing